ReviewBiotechnology and bioengineering2023
Cell factory engineering: Challenges and opportunities for synthetic biology applications.
Review in Biotechnology and bioengineering, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 21 citations in OpenAlex.
- Programmed synthesis of mesoporous protein crystals in cellular reactors.Nature nanotechnology · 2026Article
- Putative membrane protein Cgl2168 and its variant enhance thermotolerance inSynthetic and systems biotechnology · 2026Article
- Unique DNA impacts on transient Expi293Frontiers in bioengineering and biotechnology · 2026Article
- Cell Engineering for Increasing Production of Recombinant Proteins in Mammalian Cells.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- Process development for production of non-originator NISTmAb from CHO and NS0 cell lines.mAbs · 2025Article
- A novel single-vector featuring bidirectional promoters for production of bispecific antibody against rabies virus.BMC biotechnology · 2025Article
- Microalgae, Cell Factories for Antimicrobial Peptides: A Promising Response to Antibiotic Resistance.Antibiotics (Basel, Switzerland) · 2025Review
- Protein Translocation Control inBiomolecules · 2025Article
- Systematic approach for dissecting promoters and designing transform systems in microalgae.Microbial cell factories · 2025Article
- Chances and drawbacks of derepressed recombinant enzyme production in continuous cultivations withFrontiers in bioengineering and biotechnology · 2025Article
- Multiple NADPH-cytochrome P450 reductases from Lycoris radiata involved in Amaryllidaceae alkaloids biosynthesis.Plant molecular biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The production of high-quality recombinant proteins is critical to maintaining a continuous supply of biopharmaceuticals, such as therapeutic antibodies. Engineering mammalian cell factories presents a number of limitations typically associated with the proteotoxic stress induced upon aberrant accumulation of off-pathway protein folding intermediates, which eventually culminate in the induction of apoptosis. In this review, we will discuss advances in cell engineering and their applications at different hierarchical levels of control of the expression of recombinant proteins, from transcription and translational to posttranslational modifications and subcellular trafficking. We also highlight challenges and unique opportunities to apply modern synthetic biology tools to the design of programmable cell factories for improved biomanufacturing of therapeutic proteins.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.